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Australia, New Zealand, and Denmark. In the US it is projected that can-
cer will surpass heart disease as the nation's leading killer by 2030. In
2015 more than 1.65 million Americans will be diagnosed with cancer
and 590,000 will die from it (SEER, 2015). Currently nearly 15 million
people in the US are either living with cancer or are cancer survivors.
Because cancer is such a widespread, pernicious disease that requires
signiﬁcant, long-term medical intervention, the economic costs are
considerable. Current estimates of the cost of cancer care in the US
are pegged at $150 billion/year and are expected to rise to nearly
$173 billion/year by 2020.
Since 1971, global spending on cancer research has exceeded
$200 billion,with theUS accounting for nearly 60% of thatﬁgure. Thanks
to this investment, 5-year cancer survival rates in the US have improved
from 48.9% in 1975 to 68.7% in 2015 (SEER, 2015). However, most of
these improvements in survival have been attributed to improved
screening and better detection techniques rather than improved treat-
ment. Screening allows cancer to be detected at its earliest stages
where intervention is most effective. Survival rates for most forms of
metastatic or late stage (stage 3 or 4) disease have remained largely
unchanged for the past 40 years (Kolata, 2009). Furthermore, the US
cancer death rate, adjusted for population age and size, has decreased
by just 5% since 1950. This is in marked contrast to death rates
from stroke and heart disease, which have dropped by 70% over the
same period (Kolata, 2009). These same disheartening trends in can-
cer outcomes have been mirrored in many other industrialized
countries.
Why has progress been so slow? The short answer is that cancer is a
very complex disease. Decades of detailed genetic analysis have re-
vealed that there are nearly 1000 known cancer-associated genes in
humans (~250 oncogenes, ~700 tumor suppressors). Given that cells
typically need 2 or more mutations in these cancer-associated genes
to become carcinogenic, simple mathematics indicates that there
could be N1 million different cancer genotypes. How can anyone hope
to treat a million different diseases? Recent genetic data is even more
discouraging. Comprehensive sequence analysis of nearly 1 million
tumor samples over the past decade has identiﬁed N2 million coding
point mutations, N6 million noncoding mutations, N10,000 gene
fusions, ~61,000 genome rearrangements, ~700,000 abnormal copyE-mail address: dwishart@ualberta.ca.
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(Forbes et al., 2015). Whole genome sequencing of tumor samples in
one study showed between 10,000–50,000 different single nucleotide
variants in tumor cells compared to adjacent normal tissue (Lee et al.,
2010). In simple terms, tumor cells are a genetic “trainwreck”. Using ge-
netic ﬁngerprinting of tumors in order to design custom, tumor-speciﬁc
drugs appears to be a daunting challenge.
However, a glimmer of hope is nowon the horizon. Detailed analysis
of the function of most oncogenes and tumor suppressors suggested
that many play a key role in cellular metabolism (Boroughs and
DeBerardinis, 2015). Indeed, it appears that many of the seemingly
inﬁnite number of cancer mutations and cancer genes in humans
seem to affect three major metabolic pathways: 1) aerobic glycolysis;
2) glutaminolysis; and 3) one-carbon metabolism. These pathways
allow cancer cells to shift from simply producing ATP (energy) to gener-
ating large quantities of amino acids, nucleotides, fatty acids and other
intermediates needed for rapid cell growth and division. Could it be
that cancer is essentially a metabolic disease? Interestingly, prior to
1970, most cancer researchers thought of cancer as a metabolic disor-
der. In 1927 Otto Warburg noticed that cancer cells exhibited a distinct
metabolic phenotype, consumingup to 200×more glucose thannormal
cells (the “Warburg effect”). Indeed, based on Warburg's inﬂuence,
most cancer drugs discovered in the 1950s and 1960s were called “an-
timetabolites”. However, withWarburg's death in 1970 and the discov-
ery of oncogenes in 1971, most cancer researchers shifted their thinking
to view cancer as a genetic disease rather than a metabolic disease. The
“re-discovery” of cancer as a metabolic disorder largely occurred in the
lastﬁve years. This shift in thinkinghasmostly beendue to the increased
accessibility of metabolomics and the discovery, via metabolomics, of
“oncometabolites”. Oncometabolites are endogenous metabolites whose
accumulation initiates or sustains tumor growth and metastasis. The
ﬁrst oncometabolite to be discoveredwas 2-hydroxyglutarate, a relatively
rare metabolite that is found in high concentrations in gliomas (Ward
et al., 2010). This compound appears to (indirectly) alter histone meth-
ylation patterns that ultimately lead to carcinogenesis. Since the discov-
ery of 2-hydroxyglutarate many other oncometabolites have been
identiﬁed or subsequently “reclassiﬁed”. These include: fumarate
(renal cell carcinoma), succinate (paraganglioma), sarcosine (prostate
cancer), glycine (breast cancer), glucose (most cancers), glutamine
(myc-dependent cancers), serine (most cancers), asparagine (leuke-
mia), choline (prostate, brain, breast cancer), lactate (most cancers)
and polyamines (most cancers). Almost all of these oncometabolitesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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What does this mean for cancer diagnosis and treatment? For one, it
suggests that early stage cancermay be detectable by looking for simple
metabolic changes such as increased levels of acetate, lactate, serine,
sarcosine, asparagine, dimethylspermine, betaine or choline in blood,
saliva, breath or urine. Indeed recent publications have demonstrated
impressive results for colonic polyps and early stage pancreatic cancer
and suggest that more cancer metabolite biomarkers may be on the
way (Wang et al., 2014; Xie et al., 2015). Given that more than 95% of
cancers are of somatic origin and cannot be detected via genetic screen-
ing, metabolite screening could be a fast, cost-efﬁcient way of identify-
ing early stage cancers or pre-cancers. As noted above, early cancer
detection is still the best route to ensure optimal treatment outcomes.
A second opportunity lies in the ability to metabolically phenotype can-
cers using metabolomic blood tests, PET imaging or magnetic resonance
spectroscopy (Qu et al., 2012). Some cancers appear to prefer aerobic gly-
colysis, while others dependmore on glutaminolysiswhile still others use
a combination of two or more of these pathways. Using non-invasive
methods to identify which of the seven different “metabotypes” a given
tumor might belong to, or which oncometabolites it is accumulating,
would allow for better customization or informed adjustment of cancer
therapies. The third opportunity lies in the relative ease of developing or
repurposing drugs for well-studied metabolic enzymes. Some existing
drugs are already showing impressive results as anticancer therapies,
including metformin (a diabetic biguanide that inhibits hexokinase II),
dichloroacetate (a lactic acidosis drug that inhibits pyruvate dehydroge-
nase kinase), ritonavir (an antiviral drug that also inhibits glucose
transporters) and orlistat (an anti-obesity drug that blocks fatty acid syn-
thase). Likewise diets or medical foods that signiﬁcantly reduce the
amount of glucose (ketogenic diets) or the amount of non-essential
amino acids have shown good promise in stopping or reducing tumor
growth in animal models and even humans (Seyfried, 2012).
Aswith all new discoveries and emergingﬁelds, the excitement over
metabolism and cancer needs to be tempered with some caution. How-
ever, the bottom line is that while cancer as a genetic disease looks to beimpossibly complex, cancer as a metabolic disease appears to be re-
markably simple.Conﬂicts of Interest
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